Drug Profile
Research programme: degenerative disease therapeutics - 4SC Discovery/CRELUX/Helmholtz Zentrum Munchen
Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator 4SC Discovery; CRELUX; Helmholtz Zentrum Munchen
- Developer 4SC Discovery; CRELUX
- Class
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Tissue degeneration
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Tissue degeneration in Germany (unspecified route) before August 2023
- 28 Feb 2019 No recent reports of development identified for preclinical development in Tissue-degeneration in Germany
- 15 Apr 2016 CRELUX has been acquired by WuXi AppTec